Scarica l'app Stockscreener
24.70
0.08%
0.10
Uniqure Nv Borsa (QURE) Ultime notizie
Numero AI and Royu Merge to Redefine How Finance Teams Operate - Benzinga
Mizuho downgrades UniQure NV (QURE) - MSN
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message - Insider Monkey
What Just Happened with uniQure's Earnings and FDA Update - Kavout
Uniqure NV at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Price-Driven Insight from (QURE) for Rule-Based Strategy - Stock Traders Daily
Huntington's Disease Pipeline 2026: Therapies Under - openPR.com
UniQure NV (QURE) price target decreased by 26.57% to 37.82 - MSN
Mizuho maintains uniQure NV (QURE) outperform recommendation - MSN
QURE stock just shot up 8%uniQure’s much-talked-about Huntington’s disease therapy gets a UK boost - MSN
UBS Group AG Buys 286,465 Shares of uniQure N.V. $QURE - MarketBeat
uniQure N.V.Ordinary Shares (NQ: QURE - The Chronicle-Journal
RTW Investments and R. Wong report 2.59M shares in uniQure (NASDAQ: QURE) - Stock Titan
Tejara Capital Ltd Takes $1.01 Million Position in uniQure N.V. $QURE - MarketBeat
Q4 2025 Uniqure NV Earnings Call Transcript - GuruFocus
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
What Triggered uniQure's Sudden Stock Plunge - Kavout
uniQure NV(QURE) Stock Options Chain | Quotes & News - Moomoo
uniQure N.V. (NASDAQ: QURE) Long Term Investor Alert: Investigation of potential Wrongdoing - openPR.com
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms - marketscreener.com
Is uniQure N.V. (QURE) A Good Stock To Buy Now? - Insider Monkey
Uniqure Insider Sold Shares Worth $1,127,500, According to a Recent SEC Filing - marketscreener.com
uniQure (QURE) CMO sells 45,000 shares under 10b5-1 plan, exercises options - Stock Titan
uniQure NV | SCHEDULE 13G: Others - Moomoo
State Street (QURE) affiliates disclose 3.6% ownership, 2.26M shares - Stock Titan
UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play - Seeking Alpha
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate) - Seeking Alpha
Nan Fung Trinity HK Ltd. Purchases New Holdings in uniQure N.V. $QURE - MarketBeat
UniQure (QURE) files Form 144: 45,000 shares, vested and exercised stock listed - Stock Titan
uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
uniQure N.V. (NASDAQ:QURE) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
UniQure plans UK AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029 - MSN
uniQure N.V. (QURE) Stock Analysis: A Potential Upside of 64% Amidst Promising Gene Therapy Innovations - DirectorsTalk Interviews
(QURE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
UniQure (QURE) Q1 2026 Loss Of US$53.5m Tests Bullish Growth Narrative - Sahm
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $50 - 富途牛牛
uniQure NV | SCHEDULE 13G/A: Others - Moomoo
FMR LLC lists 1.74M UNIQURE shares (2.8%) — UNIQURE (NASDAQ: QURE) - Stock Titan
Transcript: uniQure Q1 2026 Earnings Conference Call - Sahm
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $25 to $37 - 富途牛牛
MSN Money - MSN
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $28 - 富途牛牛
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating - 富途牛牛
uniQure Q1 Earnings Call Highlights - Yahoo Finance
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
uniQure Releases Q1 2026 Financial Results - AlphaStreet
UniQure Shares Fall After Q1 Loss Widens - marketscreener.com
QURE: AMT-130 advances toward U.K. MAA, revenue rises, and cash runway extends into H2 2029 - TradingView
UniQure 1Q Loss/Shr 85c >QURE - Moomoo
0.06%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):